| Abstract |
【Abstract】Objective Sleep survey analysis of Parkinsons disease (PD) patients and its relationship with anxiety and depression.Method Retrospective analysis from January 2020 to December 2022 in our hospital for treatment of the clinical data of 130 patients with Parkinsons disease, according to the Pittsburgh sleep quality index (PSQI) score all patients were divided into sleep disorder (SD) group (n = 88), SD (n = 42).Baseline data and scores of the two groups were compared [Simple Intelligent Mental State Examination Scale (MMSE), Montreal Cognitive Assessment Scale (MoCA),) Unified Parkinsons Disease Rating Scale III (UPDRS-Ⅲ, Hamilton Anxiety Scale (HAMA), and Hamilton Depression Scale (HAMD)].Multivariate Logistic regression was used to analyze the influencing factors of SD in PD patients. Spearman correlation coefficient was used to analyze the correlation between PSQI score and PDQ-8, UPDRS-Ⅲ, HAMA and HAMD scores in PD patients.Result The proportion of doserazide tablets equivalent dose ≥600mg, PDQ-8, UPDRS-Ⅲ, HAMA and HAMD scores in SD group were higher than those in non-SD group (P < 0.05).Multiple Logistic regression analysis confirmed that equivalent dose of dopa and benserazide tablets, PDQ-8, UPDRS-Ⅲ, HAMA and HAMD were all risk factors for SD in PD patients, with P < 0.05.Correlation analysis showed that PSQI score of first PD patients was positively correlated with PDQ-8, UPDRS-Ⅲ, HAMA and HAMD (P < 0.05).Conclusion The incidence of SD in Parkinsons patients is high, and depression, anxiety, quality of life and movement disorders will induce and aggravate the severity of SD in Parkinsons patients.
|